160 related articles for article (PubMed ID: 31690516)
1. Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer.
Berenguer Frances MA; Linares-Galiana I; Cañas Cortés R; Marín I Borrás S; Gutiérrez Miguélez C; Najjari D; Slocker A; Bellobí C; Santacana M; Pané Foix M; Alonso MH; Navarro-Martin A; Comas Antón S; Guedea F
Brachytherapy; 2020; 19(1):51-59. PubMed ID: 31690516
[TBL] [Abstract][Full Text] [Related]
2. Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study.
Miyata Y; Ogo E; Abe T; Hirata H; Tsuda N; Ushijima K; Kawahara A; Akiba J; Obara H; Kakuma T
Radiat Oncol; 2023 Feb; 18(1):40. PubMed ID: 36823665
[TBL] [Abstract][Full Text] [Related]
3. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
[TBL] [Abstract][Full Text] [Related]
4. Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.
Ahn JS; Al-Habib A; Vos JA; Sohani AR; Barboza-Quintana O; Flores JP; Wen S; Rosado FG
Ann Clin Lab Sci; 2020 Mar; 50(2):213-218. PubMed ID: 32366559
[TBL] [Abstract][Full Text] [Related]
5. Radiobiological optimization comparison between pulse-dose-rate and high-dose-rate brachytherapy in patients with locally advanced cervical cancer.
Annede P; Dumas I; Schernberg A; Tailleur A; Fumagalli I; Bockel S; Mignot F; Kissel M; Deutsch E; Haie-Meder C; Chargari C
Brachytherapy; 2019; 18(3):370-377. PubMed ID: 30797698
[TBL] [Abstract][Full Text] [Related]
6. The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial.
Li R; Liu Y; Yin R; Yin L; Li K; Sun C; Zhou Z; Li P; Tong R; Xue J; Lu Y
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1432-1441. PubMed ID: 33713744
[TBL] [Abstract][Full Text] [Related]
7. Stage-related PD-L1 expression in Kaposi sarcoma tumor microenvironment.
Joest B; Kempf W; Berisha A; Peyk P; Tronnier M; Mitteldorf C
J Cutan Pathol; 2020 Oct; 47(10):888-895. PubMed ID: 32310306
[TBL] [Abstract][Full Text] [Related]
8. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.
Petereit DG; Sarkaria JN; Potter DM; Schink JC
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1267-74. PubMed ID: 10613322
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma.
Harada K; Dong X; Estrella JS; Correa AM; Xu Y; Hofstetter WL; Sudo K; Onodera H; Suzuki K; Suzuki A; Johnson RL; Wang Z; Song S; Ajani JA
Gastric Cancer; 2018 Jan; 21(1):31-40. PubMed ID: 28801853
[TBL] [Abstract][Full Text] [Related]
10. Pulsed-dose-rate vs. high-dose-rate intracavitary radiotherapy for locally advanced carcinoma of cervix: A prospective randomized study.
Kumar P; Sharma DN; Kumar S; Gandhi AK; Rath GK; Julka PK
Brachytherapy; 2016; 15(3):327-332. PubMed ID: 26996595
[TBL] [Abstract][Full Text] [Related]
11. CD163
Kubota K; Moriyama M; Furukawa S; Rafiul HASM; Maruse Y; Jinno T; Tanaka A; Ohta M; Ishiguro N; Yamauchi M; Sakamoto M; Maehara T; Hayashida JN; Kawano S; Kiyoshima T; Nakamura S
Sci Rep; 2017 May; 7(1):1755. PubMed ID: 28496107
[TBL] [Abstract][Full Text] [Related]
12. Redefining the role of pulsed-dose-rate brachytherapy in cervical cancer treatment using a preplanned approach.
Annede P; Robert C; Espenel S; Dumas I; Chargari C
Brachytherapy; 2024; 23(2):107-114. PubMed ID: 38105154
[TBL] [Abstract][Full Text] [Related]
13. Effect of smoking status and programmed death-ligand 1 expression on the microenvironment and malignant transformation of oral leukoplakia: A retrospective cohort study.
Yagyuu T; Funayama N; Imada M; Kirita T
PLoS One; 2021; 16(4):e0250359. PubMed ID: 33861793
[TBL] [Abstract][Full Text] [Related]
14. CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.
Antel K; Chetty D; Oosthuizen J; Mohamed Z; Van der Vyver L; Verburgh E
Pathology; 2021 Aug; 53(5):628-634. PubMed ID: 33558066
[TBL] [Abstract][Full Text] [Related]
15. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.
Koelblinger P; Emberger M; Drach M; Cheng PF; Lang R; Levesque MP; Bauer JW; Dummer R
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):667-675. PubMed ID: 30357969
[TBL] [Abstract][Full Text] [Related]
16. Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV Infection.
Said EA; Al-Reesi I; Al-Riyami M; Al-Naamani K; Al-Sinawi S; Al-Balushi MS; Koh CY; Al-Busaidi JZ; Idris MA; Al-Jabri AA
PLoS One; 2016; 11(6):e0158265. PubMed ID: 27348308
[TBL] [Abstract][Full Text] [Related]
17. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
[TBL] [Abstract][Full Text] [Related]
18. The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer.
Xu JY; Wang WS; Zhou J; Liu CY; Shi JL; Lu PH; Ding JL
Pancreas; 2019 Aug; 48(7):904-912. PubMed ID: 31268976
[TBL] [Abstract][Full Text] [Related]
19. Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer.
Stewart AJ; Viswanathan AN
Cancer; 2006 Sep; 107(5):908-15. PubMed ID: 16874815
[TBL] [Abstract][Full Text] [Related]
20. Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment.
Lippens L; Van Bockstal M; De Jaeghere EA; Tummers P; Makar A; De Geyter S; Van de Vijver K; Hendrix A; Vandecasteele K; Denys H
Int J Cancer; 2020 Jul; 147(2):554-564. PubMed ID: 32017078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
